Syschem (India) has secured its board’s approval for expansion of its existing plant units. The expansion includes the addition of a new manufacturing unit for Amoxicillin and Ampicillin, along with further expansion of the existing CDF unit comprising Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium. Additionally, the company will expand its Effluent Treatment Plant (ETP) and Multi-Effect Evaporator (MEE) to strengthen environmental compliance and support sustainable operations.
This expansion is expected to significantly enhance the company’s manufacturing capacity, operational efficiency, and environmental management capabilities. The estimated investment required for the expansion is around Rs 14 crore and the expanded capacities are expected to be commissioned by December, 2026.
Syschem (India) is engaged in manufacturing pesticides' namely Monocrotophos (MCP) and Dichlorvos (DDVP).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1806.45 |
| Dr. Reddys Lab | 1279.25 |
| Cipla | 1381.50 |
| Zydus Lifesciences | 1087.75 |
| Lupin | 2273.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: